Chronic Limb-Threatening Ischemia (CLTI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Chronic Limb-Threatening Ischemia (CLTI) Market Outlook

Thelansis’s “Chronic Limb-Threatening Ischemia (CLTI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Chronic Limb-Threatening Ischemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Chronic Limb-Threatening Ischemia Overview

Critical limb-threatening ischemia is a severe medical condition that occurs when there is an inadequate supply of blood and oxygen to the limbs. The narrowing of blood vessels typically causes this due to the accumulation of plaque, which prevents oxygenated blood from flowing to the limbs properly. As a result, there is a risk of tissue damage and possible amputation. This condition can be clinically defined in three ways: ischaemic rest pain for greater than two weeks duration requiring opiate analgesia, the presence of ischaemic lesions or gangrene that is objectively attributable to arterial occlusive disease, or an ankle brachial pressure index (ABPI) less than 0.5. Chronic limb ischemia results from arterial occlusive disease, most commonly atherosclerosis. This can occur in association with hypertension, hypercholesterolemia, cigarette smoking, and diabetes, as well as other conditions like Buerger's disease or thromboangiitis obliterans and some forms of arteritis. In patients with intermittent claudication, over five years, most will have stable claudication or show improvement, while 10-20% will develop worsening symptoms and 5-10% will develop critical limb ischemia.

• In the USA, Critical limb-threatening ischemia has an estimated annual incidence of 220 to 3500 cases per 1 million individuals.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: